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INTRODUCTION
Sleep bruxism is characterized by the involuntary clench-
ing or grinding of the teeth during sleep and can cause
severe health problems, including the destruction of tooth
structure, temporo-mandibular joint dysfunction, myofas-
cial pain, and severe sleep disturbances (1). Iatrogenic sleep
bruxism may be common during treatment with pyscho-
tropic medications, such as antipsychotics and antidepres-
sants, especially selective serotonin reuptake inhibitors
(SSRIs) (2). This article reports the case of a depressive
woman with paroxetine-induced sleep bruxism who was
successfully treated with buspirone.
CASE DESCRIPTION
A 38-year-old married woman who was suffering from
severe headaches, sadness, anhedonia, and feelings of
worthlessness and decreased energy and concentration
visited our outpatient clinic. This patient was diagnosed
with a depressive mood and muscle contraction headaches,
and a regimen of paroxetine was initiated with a bedtime
dose of 10 mg/day. The patient had no previous personal or
family history of any movement disorder, substance abuse or
mental illness. After 7 days at this dosage without adverse
effects, the dose was increased to 20 mg/day. At the 3-week
follow-up visit, the patient showed marked improvement
in her headaches and depressive symptoms, and she was
pleased with this treatment. However, her husband noted his
wife’s severe teeth clenching and associated loud grinding
noises during sleep. All laboratory results were within the
normal ranges, and all potential organic contributors to
depression and bruxism were excluded. The dental examina-
tion also did not reveal any abnormalities.
A few days later, the patient started to complain of jaw
pain and stiffness in the morning. As this problem caused
her distress, the dosage was reduced to 10 mg/day. Due to
the patient’s lack of improvement over the next week,
paroxetine treatment was discontinued, although the brux-
ism did not resolve after the therapy had been discontinued.
As buspirone has been shown to be useful for the
treatment of bruxism, we began to administer buspirone
to the patient at a dose of 5 mg/nightly. This dose was
eventually increased to 10 mg/nightly. Within 2 weeks of
beginning buspirone treatment, the patient and her husband
reported the disappearance of the jaw pain and stiffness, as
well as the bruxism symptoms.
DISCUSSION
Bruxism is a common movement disorder that affects 8-
21% of the population. The majority of bruxism symptoms
are mild or moderate, although rare but severe cases may
lead to serious periodontal damage, temporo-mandibular
dysfunction, sleep disturbances, jaw pain, and stiffness. As a
result, such cases must be treated with medication (3).
The neurochemical mechanism underlying the develop-
ment of bruxism remains unclear. However, recent inves-
tigations have suggested that the central dopaminergic
system (especially within the meso-cortical tract), which
controls muscular or motor activity, may be involved in the
pathophysiology of bruxism (4). It has been hypothesized
that the mechanism for SSRI-induced bruxism may involve
excessive serotonergic action on the meso-cortical neurons
arising from the ventral tegmental area. This action leads
to a dopaminergic deficit, which causes a specific form
of akathisia and akathisia-like movement of the jaw
muscles, thereby leading to bruxism (5).
Kishi described an old, depressive Japanese man who
displayed paroxetine-induced bruxism symptoms that were
effectively treated with the 5-HT1A receptor tandospirone
(6). To the best of our knowledge, the case described here is
the first reported case of paroxetine-induced sleep bruxism
to be treated successfully with buspirone.
Drug-induced movement disorders typically respond to a
reduction in drug dosage, whereas our patient exhibited no
improvement following the dose reduction or discontinua-
tion of the drug in question. As a result, these symptoms may
have been prevented through the use of buspirone alone.
Buspirone is an agonist of the 5-HT1A receptor that
increases dopaminergic neuron firing in the ventral teg-
mental area and increases the synaptic release of dopamine
in the prefrontal cortex. These effects ameliorate drug-
induced bruxism. Buspirone can also ameliorate extrapyr-
amidal side effects, such as akathisia and tardive dyskinesia,
and this property may be an additional explanation for the
bruxism-related effects of the drug (5).
Thus, the present case describes rare but important side
effects associated with the use of SSRIs. In light of our
findings, we emphasize that all clinicians should be aware
that antidepressants may cause bruxism. Furthermore,
buspirone may be an effective treatment for the bruxism
associated with the use of these medications.
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